HR0585LRB102 22556 MST 31697 r


2    WHEREAS, Breast cancer is among the most commonly
3diagnosed types of cancer and is the second leading cause of
4cancer death among women in the United States; and
5    WHEREAS, Approximately 281,550 women will be diagnosed
6with breast cancer, and nearly 43,600 will die with this
7malignancy in 2021; and
8    WHEREAS, Triple Negative Breast Cancer is one of many
9forms of breast cancer and accounts for approximately 15-30%
10of all diagnosed invasive breast cancer cases in the United
11States; and
12    WHEREAS, Of the new breast cancer cases diagnosed in 2019
13in the United States, more than 53,700 were Triple Negative
14Breast Cancer with higher prevalence among younger women,
15Black and Hispanic women, women with type 2 diabetes or
16carrying excess weight in the abdomen area, and those with
17BRCA1 mutations; and
18    WHEREAS, Due to its aggressive behavior, Triple Negative
19Breast Cancer grows quickly and is more likely to have spread
20at the time it is found and more likely to return after
21treatment than other types of breast cancer; and



HR0585- 2 -LRB102 22556 MST 31697 r

1    WHEREAS, People diagnosed with metastatic Triple Negative
2Breast Cancer have a less than 30% chance of surviving past
3five years; and
4    WHEREAS, Triple Negative Breast Cancer cells do not
5contain and are considered negative for the three key
6receptors that medicines typically target in other types of
7breast cancers; therefore, there are limited treatment options
8that can be used to treat this type of cancer; and
9    WHEREAS, Patients with an early diagnosis can often be
10treated with chemotherapy, radiation, and surgery; however,
11the limited therapies available that specifically address the
12management of Triple Negative Breast Cancer have made treating
13this disease a challenge for clinicians; and
14    WHEREAS, Recent innovations in targeted therapies have
15fueled advances in the fight against Triple Negative Breast
16Cancer; and
17    WHEREAS, Studies have shown that Triple Negative Breast
18Cancer disease-specific mortality rates are often higher if
19patients have Medicaid or Medicare or are lower socio-economic
20status, and compared with non-Hispanic white women, Black
21women are 48% less likely to receive guideline adherent care



HR0585- 3 -LRB102 22556 MST 31697 r

1and have an approximate two-fold higher mortality incidence,
2resulting in a disproportionately higher risk of death from
3Triple Negative Breast Cancer; and
4    WHEREAS, Advances in breast cancer screening and treatment
5over the last few decades have reduced the overall breast
6cancer mortality rate, yet the disproportionate impact of
7Triple Negative Breast Cancer on racial and ethnic minority
8communities raises the need for consideration of the
9underlying determinants driving the disparities; and
10    WHEREAS, It is necessary to promote Triple Negative Breast
11Cancer education, to raise awareness about the disease-related
12disparities, and to tackle inequities within the health care
13delivery, such as inadequate access to screening, diagnostic
14testing, and care, to improve early detection and survival;
15therefore, be it
18we declare March 3, 2022 as Triple Negative Breast Cancer
19Awareness Day in the State of Illinois and the month of March
202022 as Triple Negative Breast Cancer Awareness Month; and be
21it further
22    RESOLVED, That we support legislation to reduce Triple



HR0585- 4 -LRB102 22556 MST 31697 r

1Negative Breast Cancer disparities in early detection and
2survival by improving education and awareness through health
3promotion initiatives targeting underserved communities
4disproportionately impacted, by ensuring equitable access to
5and the affordability of breast cancer screening, genetic
6counseling, and diagnostic testing, by promoting cultural
7sensitivity and workforce diversity policies in health care
8provider training, and by guaranteeing timely patient access
9to clinically appropriate treatment options identified in the
10National Comprehensive Cancer Network (NCCN) guidelines; and
11be it further
12    RESOLVED, That additional legislative provisions should be
13examined to safeguard affordable, continuous, and equitable
14patient access to Triple Negative Breast Cancer related care,
15services, and medicines along the entire continuum of care.